|Bid||4.7200 x 1800|
|Ask||4.8700 x 1300|
|Day's range||4.6600 - 4.8950|
|52-week range||2.2700 - 8.3700|
|Beta (5Y monthly)||1.52|
|PE ratio (TTM)||N/A|
|Earnings date||11 May 2020|
|Forward dividend & yield||N/A (N/A)|
|1y target est||3.78|
Amneal (AMRX) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Image source: The Motley Fool. Amneal Pharmaceuticals, Inc. (NYSE: AMRX)Q1 2020 Earnings CallMay 11, 2020, 8:30 a.m. ETContents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: OperatorGood morning and welcome to the Amneal Pharmaceuticals First Quarter 2020 Earnings Conference Call.
Amneal (AMRX) delivered earnings and revenue surprises of 150.00% and 12.50%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Amneal (AMRX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) ("Amneal" or the "Company") today announced that it has received Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration (FDA) for a generic version of Butrans® (buprenorphine) Transdermal System, 5 mcg/hr, 7.5 mcg/hr, 10 mcg/hr, 15 mcg/hr and 20 mcg/hr. In addition, Amneal was granted the Competitive Generic Therapy (CGT) designation and 180 days of exclusivity for the 7.5 mcg/hr dose. Amneal immediately initiated commercialization activities across all dosages for its Buprenorphine Transdermal System. Butrans is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) ("Amneal" or the "Company") today announced that its 2020 Annual Meeting of Stockholders (the "Annual Meeting") will be a virtual meeting instead of an in-person meeting. This change is in response to the ongoing COVID-19 pandemic and is intended to protect the health and safety of Amneal’s stockholders and employees.
Amneal Pharmaceuticals could soon run out of the raw ingredients to make more of the antimalarial drug hydroxychloroquine that has been touted as a potential treatment for COVID-19 because Finland is keeping the drug for domestic use, according to the generic drugmaker's chief executives. Amneal has committed to producing about 20 million hydroxychloroquine tablets by mid-April, but will face challenges making any more after that because of difficulties acquiring active pharmaceutical ingredients from its supplier in Finland, co-CEOs Chirag and Chintu Patel said in an interview. "As the demand has increased all across the globe... the Finnish government has put out an emergency order to prioritize their domestic use for local needs," co-CEO Chintu Patel said in an interview on Tuesday.
When a coronavirus outbreak hit a Texas nursing home, Dr. Robin Armstrong reached for an unproven treatment: the anti-malaria drug hydroxychloroquine. Armstrong, the medical director at the facility, said Tuesday it is too soon to tell whether the treatment will work.
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) ("Amneal" or the "Company"), one of the largest U.S.-based generics manufacturers, and the State of Texas today announced that they are responding to the national COVID-19 health emergency. Amneal has donated 1,000,000 hydroxychloroquine sulfate tablets to the Texas State Pharmacy, which will be directly distributed to hospitals for potential use in treating COVID-19 patients.
Investors need to pay close attention to Amneal Pharmaceuticals (AMRX) stock based on the movements in the options market lately.
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) ("Amneal" or the "Company"), one of the largest U.S.-based generics manufacturers, today announced that it is responding to the national COVID-19 health emergency by building on its existing supply of hydroxychloroquine sulfate.
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) ("Amneal" or the "Company") today announced it has appointed Tasos Konidaris as Senior Vice President, Chief Financial Officer, effective March 12, 2020. Mr. Konidaris succeeds Todd Branning, who is no longer serving in this role, but remains available to the Company through March 31, 2020.
Amneal (AMRX) delivered earnings and revenue surprises of 60.00% and 3.30%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Amneal (AMRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.